China offers forward-thinking biotechs much more than an opportunity to get delayed clinical trials back on track

Weiji (危机), the Chinese term for crisis, combines the characters for “danger” and “opportunity,” an apt description of the challenge posed by COVID-19.

While most of the world struggles with pandemic containment and ‘re-opening,’ China, the world’s second largest pharmaceutical market, is nearing return to pre-pandemic operations, and the country’s effective COVID management and revamped clinical trial infrastructure can offer Western companies a destination for resuming studies. ...